[go: up one dir, main page]

BRPI9713891A - "método de diagnóstico in vitro de um vírus hiv-1 não-m, não-o, e, método de seleção e tipagem de um vírus hiv-1 não-m, não-o" - Google Patents

"método de diagnóstico in vitro de um vírus hiv-1 não-m, não-o, e, método de seleção e tipagem de um vírus hiv-1 não-m, não-o"

Info

Publication number
BRPI9713891A
BRPI9713891A BRPI9713891A BRPI9713891A BRPI9713891A BR PI9713891 A BRPI9713891 A BR PI9713891A BR PI9713891 A BRPI9713891 A BR PI9713891A BR PI9713891 A BRPI9713891 A BR PI9713891A BR PI9713891 A BRPI9713891 A BR PI9713891A
Authority
BR
Brazil
Prior art keywords
hiv
strain
group
ybf30
virus
Prior art date
Application number
BRPI9713891A
Other languages
English (en)
Inventor
Philippe Mauclere
Ibtissam Loussert-Ajaka
Francois Simon
Sentob Saragosti
Francoise Barre-Sinoussi
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Publication of BRPI9713891A publication Critical patent/BRPI9713891A/pt
Publication of BRPI9713891B1 publication Critical patent/BRPI9713891B1/pt
Publication of BRPI9713891B8 publication Critical patent/BRPI9713891B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)

Abstract

"cepa de hiv-1 não-m não-o, sequência de ácido nucleico, oligonucleotídeo, hiv-1, peptídeo, composições imunogênicas, anticorpos, processos de diagnóstico in vitro e de seleção e de tipagem de um hiv-1 de grupo não-m não-o, e, reagente e kit de diagnóstico de um hiv-1 não-m não-o". cepas de retrovírus do grupo hiv-1, não-m não-o, especialmente uma cepa denominada ybf30, fragmentos dos mesmos, assim como aplicações dos mesmos, como reagente de diagnósticos e como agente imunogênico. os hiv-1 distintos ao mesmo tempo do grupo m e do grupo o apresentam as seguintes características: pouca ou nenhuma reatividade sorológica em relação a proteínas dos grupos m e o e forte reatividade sorológica em relação a proteínas provenientes da cepa ybf30 de acordo com a invenção ou da cepa siv cpzgab; ausência de amplificação genômica com a ajuda dos iniciadores das regiões env e gag dos hiv-1 dos grupos m e o; amplificação genômica na presença dos iniciadores provenientes da cepa ybf30 de acordo com a invenção; e homologia dos produtos do gene de envoltório superior a 70% em relação à cepa ybf30.
BRPI9713891A 1996-12-09 1997-12-08 "método de diagnóstico in vitro de um vírus hiv-1 não-m, não-o, e, método de seleção e tipagem de um vírus hiv-1 não-m, não-o" BRPI9713891B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615087A FR2756843B1 (fr) 1996-12-09 1996-12-09 Souches de vih-1 non-m non-o, fragments et applications
PCT/FR1997/002227 WO1998026075A1 (fr) 1996-12-09 1997-12-08 Souches de vih-1 non-m non-o, fragments et applications

Publications (3)

Publication Number Publication Date
BRPI9713891A true BRPI9713891A (pt) 2000-02-29
BRPI9713891B1 BRPI9713891B1 (pt) 2015-08-18
BRPI9713891B8 BRPI9713891B8 (pt) 2021-07-06

Family

ID=9498464

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713891A BRPI9713891B8 (pt) 1996-12-09 1997-12-08 "método de diagnóstico in vitro de um vírus hiv-1 não-m, não-o, e, método de seleção e tipagem de um vírus hiv-1 não-m, não-o"

Country Status (14)

Country Link
US (4) US6509018B1 (pt)
EP (1) EP0946731B1 (pt)
JP (1) JP2000515768A (pt)
CN (1) CN1244896B (pt)
AT (1) ATE422544T1 (pt)
AU (1) AU737857B2 (pt)
BR (1) BRPI9713891B8 (pt)
CA (1) CA2274490C (pt)
DE (1) DE69739251D1 (pt)
DK (1) DK0946731T3 (pt)
ES (1) ES2323604T3 (pt)
FR (1) FR2756843B1 (pt)
PT (1) PT946731E (pt)
WO (1) WO1998026075A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
DE19936003A1 (de) * 1999-08-03 2001-02-15 Dade Behring Marburg Gmbh Lentivirus aus der Gruppe der Immunschwächeviren der Drillaffen(mandrillus leucophaeus) und ihre Verwendung
CA2525640C (en) * 2003-04-11 2014-10-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Multiple antigenic peptide assay for detection of hiv or siv type retroviruses
ZA200701180B (en) * 2004-08-17 2008-11-26 Roussy Inst Gustave Mutated HIV nef for modulating immunity
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
RU2355763C2 (ru) * 2006-09-13 2009-05-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот
JP2010521156A (ja) * 2007-03-16 2010-06-24 ４５４ ライフ サイエンシーズ コーポレイション Ｈｉｖ薬物耐性バリアントの検出のためのシステムおよび方法
WO2009126517A2 (en) * 2008-04-09 2009-10-15 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1
US9650668B2 (en) 2008-09-03 2017-05-16 Nabsys 2.0 Llc Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
JP5998148B2 (ja) 2010-11-16 2016-09-28 ナブシス ２．０ エルエルシー ハイブリダイズされたプローブの相対位置を検出することによる生体分子のシークエンシングのための方法
US11274341B2 (en) 2011-02-11 2022-03-15 NABsys, 2.0 LLC Assay methods using DNA binding proteins
US9914966B1 (en) 2012-12-20 2018-03-13 Nabsys 2.0 Llc Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation
EP2956550B1 (en) 2013-01-18 2020-04-08 Nabsys 2.0 LLC Enhanced probe binding

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002383A1 (en) * 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
ES2115622T5 (es) * 1990-10-17 2003-03-16 Us Health Clones moleculares de hiv-1 y usos de los mismos.
FR2707170A1 (fr) * 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
US5945301A (en) * 1995-09-29 1999-08-31 Chugai Seiyaku Kabushiki Kaisha Kinase in TGF-β family signal transduction system
US5994123A (en) * 1996-08-09 1999-11-30 Regents Of University Of Minnesota Sugarcane bacilliform virus promoter

Also Published As

Publication number Publication date
CN1244896B (zh) 2011-06-22
EP0946731A1 (fr) 1999-10-06
US8227185B2 (en) 2012-07-24
FR2756843A1 (fr) 1998-06-12
AU737857B2 (en) 2001-08-30
EP0946731B1 (fr) 2009-02-11
CA2274490A1 (fr) 1998-06-18
BRPI9713891B1 (pt) 2015-08-18
CN1244896A (zh) 2000-02-16
US7030234B2 (en) 2006-04-18
US20100184014A1 (en) 2010-07-22
US20030157660A1 (en) 2003-08-21
DK0946731T3 (da) 2009-06-22
ATE422544T1 (de) 2009-02-15
DE69739251D1 (de) 2009-03-26
AU5327298A (en) 1998-07-03
BRPI9713891B8 (pt) 2021-07-06
FR2756843B1 (fr) 1999-01-22
WO1998026075A1 (fr) 1998-06-18
ES2323604T3 (es) 2009-07-21
US6509018B1 (en) 2003-01-21
JP2000515768A (ja) 2000-11-28
PT946731E (pt) 2009-05-14
US20070190524A1 (en) 2007-08-16
US7534877B2 (en) 2009-05-19
CA2274490C (fr) 2013-02-12

Similar Documents

Publication Publication Date Title
BRPI9713891A (pt) "método de diagnóstico in vitro de um vírus hiv-1 não-m, não-o, e, método de seleção e tipagem de um vírus hiv-1 não-m, não-o"
Trono Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses
Vidal et al. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa
Novitsky et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?
Tönjes et al. Genome-wide screening, cloning, chromosomal assignment, and expression of full-length human endogenous retrovirus type K
Jeeninga et al. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G
Artenstein et al. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans
Michael et al. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort
Callahan et al. Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact orf-2 accessory gene
Huang et al. Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160 (gag-pol) and tRNA (Lys) incorporation into human immunodeficiency virus type 1
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
ATE395932T1 (de) Rekombinanter immunschwächepoxvirus
Nakamura et al. Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation
Huang et al. The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA3Lys genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1
Peeters et al. Genetic subtypes of HIV type 1 and HIV type 2 strains in commercial sex workers from Bamako, Mali
Hayashi et al. Elucidation of a conserved RNA stem-loop structure in the packaging signal of human immunodeficiency virus type 1
JOHNSON et al. Long-term observations of human immunodeficiency virus-infected chimpanzees
Zheng et al. In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domain
Borroto-Esoda et al. Equine infectious anemia virus and human immunodeficiency virus DNA synthesis in vitro: characterization of the endogenous reverse transcriptase reaction
Samuel et al. The 3′‐orf protein of human immunodeficiency virus shows structural homology with the phosphorylation domain of human interleukin‐2 receptor and the ATP‐binding site of the protein kinase family
EP0404625A3 (fr) Séquences oligonucléotidiques pour l'amplification du génome des rétrovirus du type HIV-2 et SIV, et leurs applications au diagnostic in-vitro des infections dûes à ces virus
KR970706399A (ko) 약독화 바이러스 및 그 제조 방법(attenuated viruses and method of making the same)
Bredell et al. Identification of HIV type 1 intersubtype recombinants in South Africa using env and gag heteroduplex mobility assays
van Harmelen et al. Restriction fragment length polymorphism analysis for rapid gag subtype determination of human immunodeficiency virus type 1 in South Africa
Ishak et al. Molecular evidence for infection by HTLV-2 among individuals with negative serological screening tests for HTLV antibodies

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2328 DE 18.08.2015, QUANTO AO NOME DO INVENTOR

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/97, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 26A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2752 DE 03/10/2023 POR TER SIDO INDEVIDA. CONFORME PUBLICACAO DO 16.3 NA RPI 2635, A VIGENCIA DA PATENTE TERMINOU EM 08/12/2017.